

**Supplementary Table S6:** geometric mean concentrations of Anti-Spike antibody levels by dose and time (days) since first-dose

group	measure	Days since baseline (since first AZ dose)								
		0	7	14	28	70	98	170	182	
Single	n	12	5	14	6	1	0	0	0	
	gmc (95% CI), n	2.2 (0.7,6.8) n=12	45.8 (15.2,137.8) n=5	13.8 (3.4,55.7) n=14	28.7 (4.1,201.2) n=6	-	-	-	-	
	seropositive %, (95%CI), n	75.0 (46.8-91.1); 9/12	100 (56.6-100.0); 5/5	85.7 (60.1-96.0); 12/14	100 (61.0-100.0); 6/6	100 (20.7-100.0); 1/1	-	-	-	
Two	n	77	48	60	51	63	39	3	2	
	gmc (95% CI), n	1.6 (1.0,2.6) n=77	6.5 (3.1,13.7) n=48	11.8 (6.1,23.0) n=60	27.3 (16.7,44.5) n=51	11.5 (7.3,18.2) n=63	26.0 (16.7,40.5) n=39	- n=3	- n=2	
	seropositive %, (95%CI), n	55.8 (44.7-66.4); 43/77	70.8 (56.8-81.8); 34/48	75.0 (62.8-84.2); 45/60	94.1 (84.1-98.0); 48/51	90.5 (80.7-95.6); 57/63	97.4 (86.8-99.5); 38/39	100 (43.9-100.0); 3/3	100.0 (34.2-100); 2/2	
Booster	n	17	16	16	16	19	15	14	8	
	gmc (95% CI), n	3.9 (1.1,14.2) n=17	8.5 (2.3,31.8) n=16	19.6 (5.2,73.9) n=16	37.9 (17.1,84.1) n=16	18.7 (6.9,51.1) n=19	18.4 (7.6,44.3) n=15	28.4 (14.1,57.4) n=14	35.3 (23.2,53.6) n=8	
	seropositive %, (95%CI), n	64.7 (41.3-82.7); 11/17	75.0 (50.5-89.8); 12/16	81.2 (57.0-93.4); 13/16	100.0 (80.6-100.0); 16/16	89.5 (68.6-97.1); 17/19	93.3 (70.2-98.8); 14/15	100 (78.5-100.0); 14/14	100 (67.6-100); 8/8	
Overall	n	106	69	90	73	83	54	17	10	
	gmc (95% CI), n	1.9 (1.2,2.9) n=106	8.0 (4.4,14.5) n=69	13.3 (7.8,22.5) n=90	29.4 (19.9,43.6) n=73	12.9 (8.6,19.4) n=83	23.6 (16.0,34.8) n=54	26.3 (14.0,49.6) n=17	34.2 (23.7,49.3) n=10	
	seropositive %, (95%CI), n	59.4 (49.9-68.3); 63/106	73.9 (62.5-82.8); 51/69	77.8 (68.2-85.1); 70/90	95.9 (88.6-98.6); 70/73	90.4 (82.1-95.0); 75/83	96.3 (87.5-99.0); 52/54	100 (81.6-100.0); 17/17	100 (72.2-100); 10/10	

GMC – Geometric Mean Concentration; CI – Confidence Interval